SecBot SecBot
SECBOTREPLAY Home › Report › XERS

XERS · Q3 revenue +44% YoY

Xeris Biopharma Holdings, Inc. · 8-K filed Nov 5, 2026 at 07:12 ET

At the news

BULLISHIMPACT 6/10

8-K filed Nov 5, 2026 at 07:12 ET

Xeris reported Q3 2026 total revenue of $107.2M, up 44% YoY and above the $101.7M consensus, driven by Recorlev net revenue of $71.5M (+93% YoY). GAAP net income was $11.3M vs $0.6M a year ago. The company raised full-year 2026 revenue guidance to $395M-$405M and raised its 2030 revenue outlook to over $1B, up from approximately $750M.

  • Total revenue $107.2M, up 44% YoY, above consensus of $101.7M
  • Recorlev net revenue $71.5M, up 93% YoY
  • GAAP net income $11.3M vs $0.6M YoY
  • Adjusted EBITDA $30.8M vs $17.4M YoY

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access